Jazz Pharmaceuticals (JAZZ) Misses Q3 EPS by 4c; Guides In-Line

Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q3 EPS of $2.57, $0.04 worse than the analyst estimate of $2.61. Revenue for the quarter came in at $374 million versus the consensus estimate of $389.23 million.

GUIDANCE:

Jazz Pharmaceuticals sees FY2016 EPS of $9.90-$10.30, versus the consensus of $10.06. Jazz Pharmaceuticals sees FY2016 revenue of $1.485-1.53 billion, versus the consensus of $1.51 billion.

"We have made substantial progress towards achieving our corporate objectives for 2016, delivering solid top-line growth in our commercial business, investing in broadening our hematology/oncology portfolio with the completion of the Celator acquisition and increasing our investments in R&D," said Bruce Cozadd, chairman and chief executive officer of Jazz Pharmaceuticals. "In the third quarter, we began a rolling NDA submission for Vyxeos for the treatment of acute myeloid leukemia, and we are pleased with the achievement of important clinical milestones, advancement of key R&D programs and expansion of our clinical development portfolio, all of which support our goal of developing and commercializing meaningful therapies for patients while building shareholder value."

For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.

You May Also Be Interested In

• Lockheed Martin (LMT) Tops Q1 EPS by 53c, Beats on Revenue; Offers FY24 Guidance
• Kiniksa Pharmaceuticals, Ltd. (KNSA) Misses Q1 EPS by 11c; raises guidance
• Fiserv (FI) Tops Q1 EPS by 9c; Boosts outlook